Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rebecca J. Nusbaum is active.

Publication


Featured researches published by Rebecca J. Nusbaum.


PLOS ONE | 2014

Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures.

Richard B. Pyles; Kathleen L. Vincent; Marc M. Baum; Barry L. Elsom; Aaron L. Miller; Carrie Maxwell; Tonyia Eaves-Pyles; Guangyu Li; Vsevolod L. Popov; Rebecca J. Nusbaum; Monique R. Ferguson

There is a pressing need for modeling of the symbiotic and at times dysbiotic relationship established between bacterial microbiomes and human mucosal surfaces. In particular clinical studies have indicated that the complex vaginal microbiome (VMB) contributes to the protection against sexually-transmitted pathogens including the life-threatening human immunodeficiency virus (HIV-1). The human microbiome project has substantially increased our understanding of the complex bacterial communities in the vagina however, as is the case for most microbiomes, very few of the community member species have been successfully cultivated in the laboratory limiting the types of studies that can be completed. A genetically controlled ex vivo model system is critically needed to study the complex interactions and associated molecular dialog. We present the first vaginal mucosal culture model that supports colonization by both healthy and dysbiotic VMB from vaginal swabs collected from routine gynecological patients. The immortalized vaginal epithelial cells used in the model and VMB cryopreservation methods provide the opportunity to reproducibly create replicates for lab-based evaluations of this important mucosal/bacterial community interface. The culture system also contains HIV-1 susceptible cells allowing us to study the impact of representative microbiomes on replication. Our results show that our culture system supports stable and reproducible colonization by VMB representing distinct community state types and that the selected representatives have significantly different effects on the replication of HIV-1. Further, we show the utility of the system to predict unwanted alterations in efficacy or bacterial community profiles following topical application of a front line antiretroviral.


Scientific Reports | 2016

Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1.

Rebecca J. Nusbaum; Veronica E. Calderon; Matthew B. Huante; Putri Sutjita; Sudhamathi Vijayakumar; Katrina L Lancaster; Robert L. Hunter; Jeffrey K. Actor; Jeffrey D. Cirillo; Judith F. Aronson; Benjamin B. Gelman; Joshua G. Lisinicchia; Gustavo Valbuena; Janice J. Endsley

Co-infection with HIV increases the morbidity and mortality associated with tuberculosis due to multiple factors including a poorly understood microbial synergy. We developed a novel small animal model of co-infection in the humanized mouse to investigate how HIV infection disrupts pulmonary containment of Mtb. Following dual infection, HIV-infected cells were localized to sites of Mtb-driven inflammation and mycobacterial replication in the lung. Consistent with disease in human subjects, we observed increased mycobacterial burden, loss of granuloma structure, and increased progression of TB disease, due to HIV co-infection. Importantly, we observed an HIV-dependent pro-inflammatory cytokine signature (IL-1β, IL-6, TNFα, and IL-8), neutrophil accumulation, and greater lung pathology in the Mtb-co-infected lung. These results suggest that in the early stages of acute co-infection in the humanized mouse, infection with HIV exacerbates the pro-inflammatory response to pulmonary Mtb, leading to poorly formed granulomas, more severe lung pathology, and increased mycobacterial burden and dissemination.


PLOS ONE | 2013

Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis.

Manjula Gunawardana; Madeline Mullen; John A. Moss; Richard B. Pyles; Rebecca J. Nusbaum; Jignesh Patel; Kathleen L. Vincent; Charles Wang; Chao Guo; Yate Ching Yuan; Charles Warden; Marc M. Baum

Background Pre-exposure chemoprophylaxis (PrECP) using antiretroviral agents is a promising strategy for the prevention of sexual HIV transmission in women. Molecular transporters in the human vaginal tract (VT) may play a pivotal role in determining drug disposition and, consequently, pharmacodynamic outcomes in these efforts. Little is known, however, on the expression of these transporters in vaginal tissues, representing a critical knowledge gap. Methodology/Principal Findings Our study analyzed the genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women undergoing gynecologic surgeries. The analysis revealed that, unexpectedly, a large number (43%) of gene isoforms corresponding to membrane transporters were over-expressed (above the median expression level) in all samples. A subset of 12 highly expressed membrane transporters was identified and contained 10 members (83%) of the solute carrier superfamily. The largest difference in membrane transporter gene expression was observed across subjects, but more subtle differential expression also was found along the anterior-posterior axis of the VT. Cross-validation of the microarray analyses with measurements RT-qPCR demonstrated high concordance between these data sets. Immunofluorescence labeling of membrane transporter proteins in vaginal tissues was highly dependent on tissue/cell types. Conclusions/Significance Antiretroviral PrECP drugs currently under evaluation are substrates for molecular transporters that were commonly expressed, but fell into both over- or under-expressed categories in all samples, suggesting a complex role for carrier-mediated processes in determining the disposition of these xenobiotics in vaginal tissues. These findings hold important implications for the successful development of products, either oral or intravaginal, for female-controlled HIV PrECP.


Tuberculosis | 2013

In vitro model of mycobacteria and HIV-1 co-infection for drug discovery

Sudhamathi Vijayakumar; Sarah Finney John; Rebecca J. Nusbaum; Monique R. Ferguson; Jeffrey D. Cirillo; Omonike Olaleye; Janice J. Endsley

Tuberculosis (TB) has become a global health threat in the wake of the Human Immunodeficiency Virus (HIV) pandemic and is the leading cause of death in people with HIV/AIDS. Treatment of patients with Mycobacterium tuberculosis (Mtb)/HIV co-infection is complicated by drug interactions and toxicity that present huge challenges for clinical intervention. Discovery efforts to identify novel compounds with increased effectiveness and decreased drug-drug interactions against Mtb, HIV-1, or both, would be greatly aided by the use of a co-infection model for screening drug libraries. Currently, inhibitors of Mtb are screened independently in mycobacterial cell cultures or target based biochemical screens and less often in macrophages or peripheral blood leukocytes. Similarly, HIV-1 drugs are screened in vitro independently from anti-mycobacterial compounds. Here, we describe an in vitro model where primary human peripheral blood mononuclear cells or monocyte-derived macrophages are infected with Mycobacterium bovis BCG and HIV-1, and used to evaluate drug toxicity and activity in a co-infection setting. Our results with standard compounds (e.g. Azidothymidine, Rifampicin) demonstrate the utility of this in vitro model to evaluate drug effectiveness relevant to cellular toxicity, HIV-1 replication, and intracellular mycobacterial growth, through the use of ELISA, bacterial enumeration, and multi-variate flow cytometry. This model and associated assays have great value in accelerating the discovery of compounds for use in Mtb/HIV-1 co-infected patients.


Journal of Virology | 2017

Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection

Olivier Escaffre; Tais B. Saito; Terry L. Juelich; Tetsuro Ikegami; Jennifer K. Smith; David Perez; Colm Atkins; Corri B. Levine; Matthew B. Huante; Rebecca J. Nusbaum; Janice J. Endsley; Alexander N. Freiberg; Barry Rockx

ABSTRACT Nipah virus (NiV) is a zoonotic emerging paramyxovirus that can cause fatal respiratory illness or encephalitis in humans. Despite many efforts, the molecular mechanisms of NiV-induced acute lung injury (ALI) remain unclear. We previously showed that NiV replicates to high titers in human lung grafts in NOD-SCID/γ mice, resulting in a robust inflammatory response. Interestingly, these mice can undergo human immune system reconstitution by the bone marrow, liver, and thymus (BLT) reconstitution method, in addition to lung tissue engraftment, giving altogether a realistic model to study human respiratory viral infections. Here, we characterized NiV Bangladesh strain (NiV-B) infection of human lung grafts from human immune system-reconstituted mice in order to identify the overall effect of immune cells on NiV pathogenesis of the lung. We show that NiV-B replicated to high titers in human lung grafts and caused similar cytopathic effects irrespective of the presence of human leukocytes in mice. However, the human immune system interfered with virus spread across lung grafts, responded to infection by leukocyte migration to small airways and alveoli of the lung grafts, and accelerated oxidative stress in lung grafts. In addition, the presence of human leukocytes increased the expression of cytokines and chemokines that regulate inflammatory influx to sites of infection and tissue damage. These results advance our understanding of how the immune system limits NiV dissemination and contributes to ALI and inform efforts to identify therapeutic targets. IMPORTANCE Nipah virus (NiV) is an emerging paramyxovirus that can cause a lethal respiratory and neurological disease in humans. Only limited data are available on NiV pathogenesis in the human lung, and the relative contribution of the innate immune response and NiV to acute lung injury (ALI) is still unknown. Using human lung grafts in a human immune system-reconstituted mouse model, we showed that the NiV Bangladesh strain induced cytopathic lesions in lung grafts similar to those described in patients irrespective of the donor origin or the presence of leukocytes. However, the human immune system interfered with virus spread, responded to infection by leukocyte infiltration in the small airways and alveolar area, induced oxidative stress, and triggered the production of cytokines and chemokines that regulate inflammatory influx by leukocytes in response to infection. Understanding how leukocytes interact with NiV and cause ALI in human lung xenografts is crucial for identifying therapeutic targets.


Scientific Reports | 2018

Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis

Charles B. Chesson; Matthew B. Huante; Rebecca J. Nusbaum; Aida G. Walker; Tara M. Clover; Jagannath Chinnaswamy; Janice J. Endsley; Jai S. Rudra

Bacillus Calmette-Guerin (BCG) is the only vaccine against TB and has limited protection efficacy, which wanes past adolescence. Multifunctional CD8+ T cells (IFN-γ+/TNF-α+/IL-2+) are associated with lower reactivation risk and enhanced control of active Mtb infection. Since boosting with BCG is contraindicated, booster vaccines that augment T cell immunity in the lungs of BCG-vaccinated individuals are urgently needed. We developed a vaccination strategy based on self-assembling peptide nanofibers presenting Mtb-specific CD8+ or CD4+ T cell epitopes that induce high frequency and antigen-specific effector memory T cells producing IFN-γ and IL-2. Intranasal immunization with peptide nanofibers was well tolerated in mice leading to increased antigen-specific CD8+ T cell population in the lungs. Co-assembled nanofibers of CD8+ T cell epitopes and toll-like receptor 2 (TLR2) agonists induced a 8-fold expansion in multifunctional CD8+ T cell populations in the lungs of vaccinated mice. Aerosol challenge with Mtb in BCG-primed and nanofiber-boosted mice provided an additional 0.5-log CFU reduction in lung bacterial load and indicating enhanced protection compared to BCG alone. Together, these data suggest that heterologous prime-boost with BCG and peptide nanofiber vaccines induces cell mediated immunity in the lung, reduces bacterial burden, and is a potentially safer alternative for boosting BCG-primed immunity.


PLOS Neglected Tropical Diseases | 2018

Host gene expression profiles in ferrets infected with genetically distinct Henipavirus strains

Alberto J. Leon; Viktoriya Borisevich; Nahal Boroumand; Robert L. Seymour; Rebecca J. Nusbaum; Olivier Escaffre; Luoling Xu; David J. Kelvin; Barry Rockx

Henipavirus infection causes severe respiratory and neurological disease in humans that can be fatal. To characterize the pathogenic mechanisms of henipavirus infection in vivo, we performed experimental infections in ferrets followed by genome-wide gene expression analysis of lung and brain tissues. The Hendra, Nipah-Bangladesh, and Nipah-Malaysia strains caused severe respiratory and neurological disease with animals succumbing around 7 days post infection. Despite the presence of abundant viral shedding, animal-to-animal transmission did not occur. The host gene expression profiles of the lung tissue showed early activation of interferon responses and subsequent expression of inflammation-related genes that coincided with the clinical deterioration. Additionally, the lung tissue showed unchanged levels of lymphocyte markers and progressive downregulation of cell cycle genes and extracellular matrix components. Infection in the brain resulted in a limited breadth of the host responses, which is in accordance with the immunoprivileged status of this organ. Finally, we propose a model of the pathogenic mechanisms of henipavirus infection that integrates multiple components of the host responses.


Immunity | 2013

Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol

Su-Yang Liu; Roghiyh Aliyari; Kelechi Chikere; Guangming Li; Matthew D. Marsden; Jennifer K. Smith; Olivier Pernet; Haitao Guo; Rebecca J. Nusbaum; Jerome A. Zack; Alexander N. Freiberg; Lishan Su; Benhur Lee; Genhong Cheng


Journal of Immunology | 2015

A small animal model of immune reconstitution inflammatory syndrome following antiretroviral therapy (CAM1P.159)

Matthew B. Huante; Rebecca J. Nusbaum; Sudhamathi Vijayakumar; Putri Sutjita; Jeffrey D. Cirillo; Monique R. Ferguson; Benjamin B. Gelman; Gustavo Valbuena; Janice J. Endsley


Journal of Immunology | 2014

Pro-inflammatory response and defective bactericidal activity by Mycobacterium tuberculosis/HIV-1 co-infected human macrophages (INC7P.421)

Matthew B. Huante; Rebecca J. Nusbaum; Sudhamanthi Vijayakumar; Veronica E. Calderon; Putri Sutjita; Yenni Goez-Rivillas; Robert Hunter Hunter; Jeffrey K. Actor; Jeffrey D. Cirillo; Monique R. Ferguson; Gustavo Valbuena; Janice J. Endsley

Collaboration


Dive into the Rebecca J. Nusbaum's collaboration.

Top Co-Authors

Avatar

Janice J. Endsley

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Matthew B. Huante

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Gustavo Valbuena

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Monique R. Ferguson

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Putri Sutjita

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Jeffrey K. Actor

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Sudhamathi Vijayakumar

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Veronica E. Calderon

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar

Alexander N. Freiberg

University of Texas Medical Branch

View shared research outputs
Researchain Logo
Decentralizing Knowledge